# Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

> **NCT05683834** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 25 (actual)

## Conditions studied

- Epstein-Barr Virus Infection
- Infectious Mononucleosis
- Herpesvirus

## Interventions

- **DRUG:** Matrix-M1 Adjuvant
- **DRUG:** EBV gp350-Ferritin Vaccine
- **OTHER:** Placebo Comparator

## Key facts

- **NCT ID:** NCT05683834
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-22
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-04-20
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05683834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05683834, "Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05683834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*